Is Eli Lilly (LLY) Priced For Perfection After Raised Guidance?

Eli Lilly has turned into one of the most closely watched stocks in healthcare after a powerful multi‑year rally. That naturally raises a blunt question for anyone looking at the chart today: Are investors paying a price that its actual cash flows can support, or has enthusiasm run ahead of what the business is currently generating?

• Over the past 5 years, Eli Lilly has delivered a very large total return of about 4.4x, so any fresh buyer today is effectively betting that future cash flows will keep pace with that step up in expectations.
• Recent data and product news around obesity, diabetes and oncology treatments can influence how the market thinks about Eli Lilly's future revenue durability, cash generation and the timing of that cash coming in.
• What if you looked at Eli Lilly through its earnings instead? See what Eli Lilly's 41.9x P/E says about the price.

The issue now is whether the current share price is adequately explained by the cash flows implied by the Discounted Cash Flow (DCF) intrinsic value estimate.

If you want more ideas built around clear cash flow stories rather than just momentum charts, start a watchlist from a focused screen of 33 high quality undervalued stocks.

Is Eli Lilly Still Cheap on Cash Flow?

The Discounted Cash Flow model here takes Eli Lilly’s projected free cash generation and works back to what that stream could be worth today. On the latest figures, the business produced about $13.6b of free cash flow over the last twelve months in $ terms, and the model assumes that this climbs materially over the next decade before growth tapers to a steadier pace.

Those projections imply rising cash available to shareholders that, when discounted, point to an intrinsic worth meaningfully above the current $1,257.03 share price. Because the Discounted Cash Flow (DCF) outcome already bakes in higher future contributions from obesity, diabetes and oncology products, the gap suggests the market is still putting a conservative lid on how durable that cash generation could be. Because recent guidance increases and pipeline news keep reinforcing the long term cash flow story, the current pricing looks more cautious than the DCF math implies. Find out what Eli Lilly could be worth using our Discounted Cash Flow (DCF) estimate.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where the valuation puzzle leaves off. They set out the specific assumptions on future growth, profitability and earnings power that would need to hold for Eli Lilly's shares to be worth materially more or materially less than today’s market price. Each scenario ties a fair value to a clear story about potential catalysts and key risks so you can track which version of events is unfolding over time on the Community page.

The Eli Lilly community splits between those who see room left in the GLP 1 story and those who worry the market has already paid up for it.

Bull case: 5% undervalued

"The current valuation implies investors already price Eli Lilly for very strong long-term growth in incretin medicines and newer areas like oncology and neuroscience, yet this narrative holds that the stock is still undervalued..."

Discover why this Narrative puts Eli Lilly at 5% undervalued.

Bear case: 6% overvalued

"P/E ratio is currently quite high at the moment but is reflected based on projected growth..."

Explore why this Narrative puts Eli Lilly at 6% overvalued.

One more angle on Eli Lilly that could change the whole story

Cash flow models only tell you what the business might produce, not how the people in charge choose to allocate it or what they are rewarded for doing with it. See who runs Eli Lilly and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com